Acceleron Careers


At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular, and pulmonary diseases.

  • Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.
  • ACE-083 is being studied in a two-part Phase 2 trial for the treatment of Charcot-Marie-Tooth (CMT) disease.
  • In our pulmonary program, our newest disease focus area, we have initiated the PULSAR and SPECTRA Phase 2 trials in pulmonary arterial hypertension (PAH).

The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to, where you will find a full description and contact information.

Drug Study Phase Disease
Luspatercept MEDALIST Phase III* Lower-Risk MDS
Luspatercept COMMANDS Phase III* Low or Intermediate Risk MDS
Luspatercept BEYOND Phase II* Beta-Thalassemia
Luspatercept Phase II* Myelofibrosis
Luspatercept Phase II Extension MDS
Luspatercept Phase II Extension Beta-Thalassemia
Luspatercept Phase II Anemia in Lower-Risk MDS
Luspatercept Phase II Beta-Thalassemia
ACE-083 Phase II Facioscapulohumeral Muscular Dystrophy
ACE-083 Phase II Charcot-Marie-Tooth Disease
Sotatercept PULSAR Phase II Pulmonary Arterial Hypertension
Sotatercept SPECTRA Phase II Pulmonary Arterial Hypertension
Acceleron trials listed as recruiting or active on

* Bristol-Myers Squibb-sponsored